Halozyme Therapeutics, Inc. (HALO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
HALO Revenue Growth
Revenue Breakdown (FY 2025)
HALO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
HALO Revenue Analysis (2014–2025)
As of May 8, 2026, Halozyme Therapeutics, Inc. (HALO) generated trailing twelve-month (TTM) revenue of $1.40 billion, reflecting explosive growth of +51.6% year-over-year. The most recent quarter (Q4 2025) recorded $451.8 million in revenue, up 27.5% sequentially.
Looking at the longer-term picture, HALO's 5-year compound annual growth rate (CAGR) stands at +39.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $1.40 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows HALO's business is primarily driven by Royalty (54%), Product (23%), and Collaborative Agreements (9%). With over half of revenue concentrated in Royalty, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+82.6% YoY), IONS (+47.5% YoY), and ARWR (+14.1% YoY), HALO has underperformed the peer group in terms of revenue growth. Compare HALO vs ALNY →
HALO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| HALOCurrent | $1.4B | +51.6% | +39.2% | 58.4% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% |
HALO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.40B | +37.6% | $1.09B | 78.1% | $816.3M | 58.4% |
| 2024 | $1.02B | +22.4% | $855.9M | 84.3% | $551.5M | 54.3% |
| 2023 | $829.3M | +25.6% | $636.9M | 76.8% | $337.6M | 40.7% |
| 2022 | $660.1M | +48.9% | $520.8M | 78.9% | $267.5M | 40.5% |
| 2021 | $443.3M | +65.7% | $361.9M | 81.6% | $275.9M | 62.2% |
| 2020 | $267.6M | +36.5% | $224.2M | 83.8% | $144.3M | 53.9% |
| 2019 | $196.0M | +29.1% | $150.4M | 76.8% | $-67,610,000 | -34.5% |
| 2018 | $151.9M | -52.0% | $141.7M | 93.3% | $-69,330,000 | -45.7% |
| 2017 | $316.6M | +115.8% | $285.5M | 90.2% | $81.0M | 25.6% |
| 2016 | $146.7M | +8.6% | $113.5M | 77.4% | $-83,210,000 | -56.7% |
See HALO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HALO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HALO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHALO — Frequently Asked Questions
Quick answers to the most common questions about buying HALO stock.
Is HALO's revenue growth accelerating or slowing?
HALO revenue is accelerating at +51.6% year-over-year, exceeding the 5-year CAGR of +39.2%. TTM revenue reached $1.4B. Growth momentum has increased versus prior periods.
What is HALO's long-term revenue growth rate?
Halozyme Therapeutics, Inc.'s 5-year revenue CAGR of +39.2% reflects the sustained expansion pattern. Current YoY growth of +51.6% is above this long-term average.
How is HALO's revenue distributed by segment?
HALO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.